Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· June 2, 2026

Phison Collaborates with Intel to Bring Larger Local AI Workloads to Intel AI PC Platforms

View original at finance.yahoo.com
Phison Collaborates with Intel to Bring Larger Local AI Workloads to Intel AI PC Platforms Phison and Intel collaborate to bring larger local AI workloads to Intel AI PC Platforms Phison's Pascari aiDAPTIV™ removes local memory constraints on client PCs, enabling larger MoE AI models and agentic AI applications TAIPEI,…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AI PCs are evolving into platforms for more sophisticated local AI workloads, and aiDAPTIV helps expand available memory for AI workloads on Intel AI PC platforms, allowing OEMs, developers and end users to run more capable AI applications locally while maintaining privacy and infrastructure efficiency.

    60% confidence
  • Phison and Intel are working to support ISV evaluations, technical demonstrations and optimized workloads for public performance claims.

    60% confidence
  • In Phison testing, aiDAPTIV enabled a 26B-parameter model to run on a system with 16GB of DRAM, compared with 32GB of DRAM required without aiDAPTIV in the same test environment.

    60% confidence
  • aiDAPTIV addresses memory constraints by extending effective AI working memory across system DRAM and high-performance, extreme-endurance NAND flash, reducing DRAM required for certain local AI workloads and supporting runtime features such as KV cache reuse.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com